Hormone Sensitive Metastatic Disease: Tumor Boards

Product ID : HSMTB16
Price: $15.00
You will receive a link to your product from customerservice@asco.org within 1 hour of purchase confirmation. Shipping charges do not apply to digital products.
E-mail to a friend



This is a case-based activity that includes discussion of a 36-year-old woman who originally presented at 18 weeks gestation with clinical T2N0, grade 3 invasive ductal carcinoma of the right breast. The tumor was ER+, PR+, and HER2 negative.

At the end of this course, participants should understand:

1. Explain how to incorporate recent evidence-based guideline recommendations and new data to select first-line therapy for women with hormone sensitive advanced breast cancer
2. Discuss the evolving role of ovarian suppression in the treatment of premenopausal women with early or advanced hormone sensitive breast cancer

IMPORTANT NOTE: This course expires on October 28, 2019. Participants must complete all necessary course components by this date.

Purchase the 2016 ASCO Tumor Boards Bundle to access to all 2016 ASCO Tumor Boards for added savings. Purchased separately, these items would be $180 altogether. When bundled, you save $55.

Recommended Products